Wall Street Zen Upgrades Cabaletta Bio (NASDAQ:CABA) to Sell

Cabaletta Bio (NASDAQ:CABA) was upgraded by analysts at Wall Street Zen from a “strong sell” rating to a “sell” rating in a report issued on Saturday, Wall Street Zen reports.

Other research analysts also recently issued research reports about the stock. Wells Fargo & Company decreased their price objective on shares of Cabaletta Bio from $4.00 to $3.00 and set an “equal weight” rating for the company in a research report on Friday, August 14th. Weiss Ratings restated a “sell (d-)” rating on shares of Cabaletta Bio in a research report on Thursday, October 15th. TD Cowen upgraded Cabaletta Bio to a “strong-buy” rating in a research note on Monday, August 24th. HC Wainwright reiterated a “buy” rating and set a $16.00 price target on shares of Cabaletta Bio in a research report on Tuesday, September 1st. Finally, William Blair raised Cabaletta Bio to a “strong-buy” rating in a report on Wednesday, September 23rd. Two equities research analysts have rated the stock with a Strong Buy rating, five have assigned a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $15.60.

Cabaletta Bio Price Performance

Cabaletta Bio stock opened at $1.30 on Friday. The firm has a market cap of $220.41 million, a price-to-earnings ratio of -0.92 and a beta of 3.56. Cabaletta Bio has a 52 week low of $1.18 and a 52 week high of $4.23. The business’s 50-day moving average price is $2.12 and its 200 day moving average price is $2.82.

Cabaletta Bio (NASDAQ:CABA) last announced its quarterly earnings results on Thursday, November 5th. The company reported ($0.28) earnings per share for the quarter, beating the consensus estimate of ($0.32) by $0.04. Equities analysts expect that Cabaletta Bio will post -1.29 EPS for the current year.

Institutional Trading of Cabaletta Bio

Several large investors have recently bought and sold shares of CABA. StoneX Group Inc. acquired a new stake in shares of Cabaletta Bio in the 3rd quarter valued at about $26,000. Kestra Advisory Services LLC acquired a new position in Cabaletta Bio during the first quarter worth approximately $32,000. SummitTX Capital L.P. acquired a new position in Cabaletta Bio during the first quarter worth approximately $34,000. Legal & General Group Plc acquired a new position in Cabaletta Bio during the second quarter worth approximately $34,000. Finally, HighTower Advisors LLC purchased a new stake in Cabaletta Bio in the second quarter valued at approximately $34,000.

About Cabaletta Bio

Cabaletta Bio, Inc is a clinical-stage biotechnology company focused on developing engineered T-cell therapies for patients with B cell-mediated autoimmune diseases. The company’s approach is designed to selectively eliminate disease-causing immune cells and potentially provide durable disease remission rather than relying on continuous immunosuppression.

Its lead investigational product, CABA-201, is an autologous, fully human CD19 chimeric antigen receptor T-cell therapy designed to target and eliminate CD19-positive B cells.